Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease

Abstract

C.E.R.A. has been shown to have a prolonged and comparable half-life after intravenous or subcutaneous injection, suggesting that extended administration intervals may be feasible in patients with chronic kidney disease.

Keywords

• Pharmacokinetics
• pharmacodynamics
• intravenous
• subcutaneous
• continuous
• erythropoietin
• receptor
• activator
• patients
• chronic
• kidney
• disease